Scholarlink

<p>Few studies explore the burden of mild-to-moderate atopic dermatitis (AD). We aimed to investigate disease burden in mild-to-moderate AD using real-world data from adults with AD and their physicians in the United States. Data were drawn from the Adelphi Real World AD Disease Specific Programme™, a cross-sectional survey of physicians and their patients with AD in real-world clinical practice in the US from November 2014 to February 2015. Physicians provided data for the next five eligible adults who consulted the physician. Patients had a physician-reported history of moderate-to-severe AD. Overall, 284 and 554 adults with physician-perceived mild or moderate AD at the most recent consultation, respectively, were included in the analysis. Patients with moderate AD experienced more flares (<i>p</i> &lt;.001) and had dry skin, pruritus, and cracking/raw skin day-to-day that were more severe (<i>p</i> &lt;.0001) and when experiencing a flare (<i>p</i> &lt;.05) than patients with mild AD. Adults with either mild or moderate AD used a similar number of treatments. Patients with moderate AD reported greater impact on health status, health-related quality of life, and productivity than those with mild AD. Adults with mild-to-moderate AD experienced substantial daily impact from symptoms despite multiple therapies. Unmet needs remain and more can be done to improve disease control in adults with mild-to-moderate AD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Burden of mild and moderate atopic dermatitis in adults: results from a real-world study in the United States

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月12日

查看全文
  • Jonathan I. Silverberg,
  • Peter Anderson,
  • Joseph C. Cappelleri,
  • James Piercy,
  • Mark E. Levenberg,
  • Daniela E. Myers,
  • Robert A. Gerber

摘要

Few studies explore the burden of mild-to-moderate atopic dermatitis (AD). We aimed to investigate disease burden in mild-to-moderate AD using real-world data from adults with AD and their physicians in the United States. Data were drawn from the Adelphi Real World AD Disease Specific Programme™, a cross-sectional survey of physicians and their patients with AD in real-world clinical practice in the US from November 2014 to February 2015. Physicians provided data for the next five eligible adults who consulted the physician. Patients had a physician-reported history of moderate-to-severe AD. Overall, 284 and 554 adults with physician-perceived mild or moderate AD at the most recent consultation, respectively, were included in the analysis. Patients with moderate AD experienced more flares (p <.001) and had dry skin, pruritus, and cracking/raw skin day-to-day that were more severe (p <.0001) and when experiencing a flare (p <.05) than patients with mild AD. Adults with either mild or moderate AD used a similar number of treatments. Patients with moderate AD reported greater impact on health status, health-related quality of life, and productivity than those with mild AD. Adults with mild-to-moderate AD experienced substantial daily impact from symptoms despite multiple therapies. Unmet needs remain and more can be done to improve disease control in adults with mild-to-moderate AD.